These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36682218)

  • 1. The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer.
    Kim VS; Yang H; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen AR; Tomlinson G; Alibhai SMH
    J Geriatr Oncol; 2023 Mar; 14(2):101417. PubMed ID: 36682218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer.
    Yang H; Kim VS; Timilshina N; Breunis H; Emmenegger U; Gregg R; Hansen A; Tomlinson G; Alibhai SMH
    J Geriatr Oncol; 2023 Jan; 14(1):101395. PubMed ID: 36988103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer.
    Deol ES; Sanfilippo KM; Luo S; Fiala MA; Wildes T; Mian H; Schoen MW
    J Geriatr Oncol; 2023 Jun; 14(5):101520. PubMed ID: 37263065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.
    Manokumar T; Aziz S; Breunis H; Rizvi SF; Joshua AM; Tannock IF; Alibhai SM
    J Geriatr Oncol; 2016 Mar; 7(2):81-9. PubMed ID: 26853769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
    Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
    JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
    Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
    Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
    Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer.
    Salem S; Komisarenko M; Timilshina N; Martin L; Grewal R; Alibhai S; Finelli A
    Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):601-608. PubMed ID: 28395931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
    Baciarello G; Delva R; Gravis G; Tazi Y; Beuzeboc P; Gross-Goupil M; Bompas E; Joly F; Greilsamer C; Hon TNT; Barthelemy P; Culine S; Berdah JF; Deblock M; Ratta R; Flechon A; Cheneau C; Maillard A; Martineau G; Borget I; Fizazi K;
    Eur Urol; 2022 Mar; 81(3):234-240. PubMed ID: 34789394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
    Payne H; Robinson A; Rappe B; Hilman S; De Giorgi U; Joniau S; Bordonaro R; Mallick S; Dourthe LM; Flores MM; Gumà J; Baron B; Duran A; Pranzo A; Serikoff A; Mott D; Herdman M; Pavesi M; De Santis M
    Int J Cancer; 2022 Mar; 150(5):837-846. PubMed ID: 34648657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer - a prospective multicenter study.
    Rönningås U; Holm M; Fransson P; Beckman L; Wennman-Larsen A
    BMC Palliat Care; 2024 Mar; 23(1):80. PubMed ID: 38532425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatigue, health-related quality-of-life and metabolic changes in men treated with enzalutamide or abiraterone acetate plus prednisone for metastatic castration-resistant prostate cancer: A randomised clinical trial (HEAT).
    Ternov KK; Sønksen J; Fode M; Lindberg H; Kistorp C; Bisbjerg R; Faber J; Klausen TW; Palapattu G; Østergren PB
    Eur J Cancer; 2022 Aug; 171():75-84. PubMed ID: 35709600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.
    Banna GL; Urzia V; Benanti C; Pitrè A; Lipari H; Di Quattro R; De Giorgi U; Schepisi G; Basso U; Bimbatti D; Rundo F; Libra M; Malatino L
    Support Care Cancer; 2020 Oct; 28(10):4687-4695. PubMed ID: 31960124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
    Oyenuga M; Halabi S; Oyenuga A; McSweeney S; Morgans AK; Ryan CJ; Prizment A
    Prostate; 2023 May; 83(7):688-694. PubMed ID: 36842158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
    BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
    Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
    Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.